| P50 | author | Olivier Chabre | Q72940457 |
| P2093 | author name string | V Kerlan | |
| | M-A Quemerais-Durieu | |
| P2860 | cites work | Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study | Q46077710 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 |
| | A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis | Q47871677 |
| | Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model | Q51541744 |
| | Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. | Q51607043 |
| | Lithium use and the risk of fractures. | Q51907566 |
| | Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. | Q51944796 |
| | Effects of denosumab on fracture and bone mineral density by level of kidney function | Q58970644 |
| | Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate | Q58971203 |
| | Osteoporosis Associated with Neutralizing Autoantibodies against Osteoprotegerin | Q64448940 |
| | Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells | Q78181001 |
| | Wnt signaling as a therapeutic target for bone diseases | Q83588890 |
| | Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones | Q84033150 |
| | Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients | Q84062765 |
| | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 |
| | Control of the SOST bone enhancer by PTH using MEF2 transcription factors | Q24337339 |
| | Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein | Q24536172 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 |
| | Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin | Q28261537 |
| | Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis | Q28265821 |
| | Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength | Q28274891 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis | Q28302443 |
| | Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice | Q28312170 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women | Q33786865 |
| | Sclerostin: current knowledge and future perspectives | Q33992612 |
| | Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women | Q34262453 |
| | Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 |
| | Osteoclast precursors, RANKL/RANK, and immunology | Q36324916 |
| | The role of the immune system in the pathophysiology of osteoporosis | Q36324969 |
| | Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. | Q36448809 |
| | Osteoporosis: now and the future | Q36564425 |
| | The many ways of Wnt in cancer | Q36701583 |
| | Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton | Q36774955 |
| | Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. | Q37092804 |
| | Does osteocytic SOST suppression mediate PTH bone anabolism? | Q37675392 |
| | Treatment of osteoporosis with denosumab | Q37710822 |
| | Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells | Q40927574 |
| | Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals | Q42717983 |
| | Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. | Q43038398 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. | Q45931469 |
| P304 | page(s) | S15-22 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Annales d'Endocrinologie | Q15753551 |
| P1476 | title | [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)] | |
| P478 | volume | 72 Suppl 1 | |